AZN logo

AstraZeneca (AZN) Depreciation and amortization

annual D&A:

$6.69B+$1.75B(+35.55%)
December 31, 2024

Summary

  • As of today (May 29, 2025), AZN annual depreciation & amortization is $6.69 billion, with the most recent change of +$1.75 billion (+35.55%) on December 31, 2024.
  • During the last 3 years, AZN annual D&A has risen by +$2.59 billion (+63.04%).
  • AZN annual D&A is now at all-time high.

Performance

AZN Depreciation and amortization Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAZNincome statement metrics

quarterly D&A:

$1.28B+$570.00M(+79.83%)
March 31, 2025

Summary

  • As of today (May 29, 2025), AZN quarterly depreciation & amortization is $1.28 billion, with the most recent change of +$570.00 million (+79.83%) on March 31, 2025.
  • Over the past year, AZN quarterly D&A has increased by +$29.00 million (+2.31%).
  • AZN quarterly D&A is now -53.95% below its all-time high of $2.79 billion, reached on September 30, 2021.

Performance

AZN quarterly D&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAZNincome statement metrics

TTM D&A:

$5.09B+$29.00M(+0.57%)
March 31, 2025

Summary

  • As of today (May 29, 2025), AZN TTM depreciation & amortization is $5.09 billion, with the most recent change of +$29.00 million (+0.57%) on March 31, 2025.
  • Over the past year, AZN TTM D&A has increased by +$407.00 million (+8.68%).
  • AZN TTM D&A is now -6.48% below its all-time high of $5.45 billion, reached on March 31, 2023.

Performance

AZN TTM D&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAZNincome statement metrics

AZN Depreciation and amortization Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+35.5%+2.3%+8.7%
3 y3 years+63.0%-1.9%+10.4%
5 y5 years+77.8%+52.7%+29.7%

AZN Depreciation and amortization Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+63.0%-29.3%+79.8%-6.5%+35.3%
5 y5-yearat high+130.9%-54.0%+644.1%-6.5%+78.6%
alltimeall timeat high+2656.0%-54.0%+644.1%-6.5%+1854.2%

AZN Depreciation and amortization History

DateAnnualQuarterlyTTM
Mar 2025
-
$1.28B(+79.8%)
$5.09B(+0.6%)
Dec 2024
$6.69B(+35.5%)
$714.00M(-60.7%)
$5.07B(-3.1%)
Sep 2024
-
$1.82B(+42.1%)
$5.22B(+11.4%)
Jun 2024
-
$1.28B(+1.9%)
$4.69B(+0.1%)
Mar 2024
-
$1.25B(+43.6%)
$4.69B(-5.0%)
Dec 2023
$4.93B(-6.1%)
$874.00M(-31.8%)
$4.93B(-7.2%)
Sep 2023
-
$1.28B(+0.5%)
$5.31B(-1.0%)
Jun 2023
-
$1.28B(-15.0%)
$5.37B(-1.5%)
Mar 2023
-
$1.50B(+19.8%)
$5.45B(+3.7%)
Dec 2022
$5.25B(+28.1%)
$1.25B(-6.0%)
$5.25B(+39.6%)
Sep 2022
-
$1.33B(-1.7%)
$3.76B(-27.9%)
Jun 2022
-
$1.36B(+3.7%)
$5.22B(+13.1%)
Mar 2022
-
$1.31B(-654.7%)
$4.61B(+12.5%)
Dec 2021
$4.10B(+41.6%)
-$236.00M(-108.5%)
$4.10B(-16.0%)
Sep 2021
-
$2.79B(+270.3%)
$4.88B(+68.6%)
Jun 2021
-
$753.00M(-5.5%)
$2.90B(+1.5%)
Mar 2021
-
$797.00M(+46.5%)
$2.85B(-1.5%)
Dec 2020
$2.90B(-23.0%)
$544.00M(-32.1%)
$2.90B(-27.5%)
Sep 2020
-
$801.00M(+12.8%)
$4.00B(+2.2%)
Jun 2020
-
$710.00M(-15.6%)
$3.91B(-0.4%)
Mar 2020
-
$841.00M(-48.8%)
$3.93B(+4.4%)
Dec 2019
$3.76B(+0.2%)
$1.64B(+129.5%)
$3.76B(-0.5%)
Sep 2019
-
$716.00M(-1.5%)
$3.78B(+0.5%)
Jun 2019
-
$727.00M(+7.5%)
$3.76B(+1.2%)
Mar 2019
-
$676.00M(-59.3%)
$3.72B(-0.9%)
Dec 2018
$3.75B(+23.6%)
$1.66B(+138.1%)
$3.75B(+17.4%)
Sep 2018
-
$698.00M(+2.0%)
$3.20B(+1.4%)
Jun 2018
-
$684.00M(-3.5%)
$3.15B(+2.2%)
Mar 2018
-
$709.00M(-36.0%)
$3.09B(+1.7%)
Dec 2017
$3.04B(+28.8%)
$1.11B(+69.0%)
$3.04B(+20.5%)
Sep 2017
-
$655.00M(+6.3%)
$2.52B(+1.8%)
Jun 2017
-
$616.00M(-6.4%)
$2.48B(+1.2%)
Mar 2017
-
$658.00M(+11.5%)
$2.45B(+3.8%)
Dec 2016
$2.36B(-17.4%)
$590.00M(-3.4%)
$2.36B(-5.1%)
Sep 2016
-
$611.00M(+4.1%)
$2.48B(+1.6%)
Jun 2016
-
$587.00M(+3.2%)
$2.44B(-5.0%)
Mar 2016
-
$569.00M(-20.5%)
$2.57B(-9.8%)
Dec 2015
$2.85B(-13.1%)
$716.00M(+25.4%)
$2.85B(-9.7%)
Sep 2015
-
$571.00M(-20.3%)
$3.16B(-8.1%)
Jun 2015
-
$716.00M(-15.7%)
$3.44B(+0.5%)
Mar 2015
-
$849.00M(-16.8%)
$3.42B(+4.2%)
Dec 2014
$3.28B(-28.4%)
$1.02B(+20.0%)
$3.28B(-32.6%)
Sep 2014
-
$851.00M(+21.9%)
$4.87B(+10.5%)
Jun 2014
-
$698.00M(-2.0%)
$4.40B(-5.2%)
Mar 2014
-
$712.00M(-72.7%)
$4.64B(+1.3%)
Dec 2013
$4.58B(+82.0%)
$2.60B(+571.4%)
$4.58B(+67.1%)
Sep 2013
-
$388.00M(-58.7%)
$2.74B(-11.5%)
Jun 2013
-
$939.00M(+44.2%)
$3.10B(+16.1%)
Mar 2013
-
$651.00M(-14.8%)
$2.67B(+6.0%)
Dec 2012
$2.52B(-1.3%)
$764.00M(+2.6%)
$2.52B(-7.6%)
Sep 2012
-
$745.00M(+46.1%)
$2.72B(+8.0%)
Jun 2012
-
$510.00M(+2.2%)
$2.52B(-0.0%)
Mar 2012
-
$499.00M(-48.6%)
$2.52B(-1.1%)
Dec 2011
$2.55B
$970.00M(+78.6%)
$2.55B(-11.7%)
Sep 2011
-
$543.00M(+6.3%)
$2.89B(-2.0%)
DateAnnualQuarterlyTTM
Jun 2011
-
$511.00M(-2.9%)
$2.95B(+2.8%)
Mar 2011
-
$526.00M(-59.8%)
$2.87B(+4.6%)
Dec 2010
$2.74B(+31.3%)
$1.31B(+117.1%)
$2.74B(+24.1%)
Sep 2010
-
$602.00M(+39.7%)
$2.21B(+6.7%)
Jun 2010
-
$431.00M(+7.5%)
$2.07B(-1.6%)
Mar 2010
-
$401.00M(-48.3%)
$2.10B(+0.8%)
Dec 2009
$2.09B(-20.3%)
$775.00M(+67.4%)
$2.09B(-6.8%)
Sep 2009
-
$463.00M(-0.2%)
$2.24B(-2.9%)
Jun 2009
-
$464.00M(+20.5%)
$2.31B(+0.1%)
Mar 2009
-
$385.00M(-58.5%)
$2.30B(-12.1%)
Dec 2008
$2.62B(+41.2%)
$927.00M(+74.9%)
$2.62B(+16.7%)
Sep 2008
-
$530.00M(+15.0%)
$2.25B(-1.5%)
Jun 2008
-
$461.00M(-34.3%)
$2.28B(+4.2%)
Mar 2008
-
$702.00M(+27.2%)
$2.19B(+17.9%)
Dec 2007
$1.86B(+38.0%)
$552.00M(-2.3%)
$1.86B(+7.2%)
Sep 2007
-
$565.00M(+53.1%)
$1.73B(+15.8%)
Jun 2007
-
$369.00M(-0.3%)
$1.50B(+4.4%)
Mar 2007
-
$370.00M(-13.6%)
$1.43B(+6.5%)
Dec 2006
$1.34B(+1.4%)
$428.00M(+30.1%)
$1.34B(+2.6%)
Sep 2006
-
$329.00M(+7.5%)
$1.31B(+2.0%)
Jun 2006
-
$306.00M(+8.5%)
$1.28B(-1.2%)
Mar 2006
-
$282.00M(-28.4%)
$1.30B(-2.0%)
Dec 2005
$1.33B(+4.7%)
$394.00M(+30.0%)
$1.33B(+1.7%)
Sep 2005
-
$303.00M(-5.6%)
$1.30B(+0.9%)
Jun 2005
-
$321.00M(+3.9%)
$1.29B(+1.4%)
Mar 2005
-
$309.00M(-16.9%)
$1.27B(+0.6%)
Dec 2004
$1.27B(-1.9%)
$372.00M(+27.8%)
$1.27B(-1.6%)
Sep 2004
-
$291.00M(-4.0%)
$1.29B(-12.9%)
Jun 2004
-
$303.00M(+0.3%)
$1.48B(+11.9%)
Mar 2004
-
$302.00M(-23.2%)
$1.32B(+2.3%)
Dec 2003
$1.29B(+34.7%)
$393.00M(-18.4%)
$1.29B(+11.3%)
Sep 2003
-
$481.84M(+230.7%)
$1.16B(+26.4%)
Jun 2003
-
$145.71M(-46.5%)
$919.16M(-8.6%)
Mar 2003
-
$272.45M(+4.2%)
$1.01B(+4.7%)
Dec 2002
$960.00M(+11.6%)
$261.54M(+9.2%)
$960.00M(+3.7%)
Sep 2002
-
$239.46M(+3.2%)
$925.46M(+3.4%)
Jun 2002
-
$232.00M(+2.2%)
$895.00M(+2.2%)
Mar 2002
-
$227.00M(0.0%)
$875.69M(+1.8%)
Dec 2001
$860.00M(-7.4%)
$227.00M(+8.6%)
$860.00M(+8.8%)
Sep 2001
-
$209.00M(-1.7%)
$790.44M(-5.9%)
Jun 2001
-
$212.69M(+0.7%)
$839.96M(-4.5%)
Mar 2001
-
$211.31M(+34.2%)
$879.67M(-5.3%)
Dec 2000
$929.02M(-13.1%)
$157.44M(-39.1%)
$929.02M(+20.4%)
Sep 2000
-
$258.52M(+2.4%)
$771.59M(+50.4%)
Jun 2000
-
$252.40M(-3.2%)
$513.07M(+96.8%)
Mar 2000
-
$260.66M
$260.66M
Dec 1999
$1.07B(+30.2%)
-
-
Dec 1998
$821.00M(+129.9%)
-
-
Dec 1997
$357.07M(-3.9%)
-
-
Dec 1996
$371.61M(+24.0%)
-
-
Dec 1995
$299.77M(+8.3%)
-
-
Dec 1994
$276.72M(+8.8%)
-
-
Dec 1993
$254.42M(+4.8%)
-
-
Dec 1992
$242.67M(-16.9%)
-
-
Dec 1991
$291.91M(-3.0%)
-
-
Dec 1990
$300.91M
-
-

FAQ

  • What is AstraZeneca annual depreciation & amortization?
  • What is the all time high annual D&A for AstraZeneca?
  • What is AstraZeneca annual D&A year-on-year change?
  • What is AstraZeneca quarterly depreciation & amortization?
  • What is the all time high quarterly D&A for AstraZeneca?
  • What is AstraZeneca quarterly D&A year-on-year change?
  • What is AstraZeneca TTM depreciation & amortization?
  • What is the all time high TTM D&A for AstraZeneca?
  • What is AstraZeneca TTM D&A year-on-year change?

What is AstraZeneca annual depreciation & amortization?

The current annual D&A of AZN is $6.69B

What is the all time high annual D&A for AstraZeneca?

AstraZeneca all-time high annual depreciation & amortization is $6.69B

What is AstraZeneca annual D&A year-on-year change?

Over the past year, AZN annual depreciation & amortization has changed by +$1.75B (+35.55%)

What is AstraZeneca quarterly depreciation & amortization?

The current quarterly D&A of AZN is $1.28B

What is the all time high quarterly D&A for AstraZeneca?

AstraZeneca all-time high quarterly depreciation & amortization is $2.79B

What is AstraZeneca quarterly D&A year-on-year change?

Over the past year, AZN quarterly depreciation & amortization has changed by +$29.00M (+2.31%)

What is AstraZeneca TTM depreciation & amortization?

The current TTM D&A of AZN is $5.09B

What is the all time high TTM D&A for AstraZeneca?

AstraZeneca all-time high TTM depreciation & amortization is $5.45B

What is AstraZeneca TTM D&A year-on-year change?

Over the past year, AZN TTM depreciation & amortization has changed by +$407.00M (+8.68%)
On this page